G Escherich
Overview
Explore the profile of G Escherich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stutterheim J, de Lorenzo P, van der Sluis I, Alten J, Ancliffe P, Attarbaschi A, et al.
Eur J Cancer
. 2021 Nov;
160:72-79.
PMID: 34785111
Background: The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we...
2.
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, et al.
BMC Cancer
. 2020 Jan;
20(1):16.
PMID: 31906955
Background: Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young adult (CAYA), are at a...
3.
Driessen E, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al.
Leukemia
. 2017 Dec;
31(12):2854.
PMID: 29210366
This corrects the article DOI: 10.1038/leu.2015.246.
4.
Jerchel I, Hoogkamer A, Aries I, Steeghs E, Boer J, Besselink N, et al.
Leukemia
. 2017 Oct;
32(4):931-940.
PMID: 28972594
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal...
5.
Rasche M, von Neuhoff C, Dworzak M, Bourquin J, Bradtke J, Gohring G, et al.
Leukemia
. 2017 Apr;
31(12):2807-2814.
PMID: 28443606
We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Münster (BFM) 04 protocol to determine the prognostic value of specific chromosomal...
6.
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, et al.
BMC Cancer
. 2016 Nov;
16(1):872.
PMID: 27825320
Background: Multimodality treatment improves the chance of survival but increases the risk for long-term side effects in young cancer survivors, so-called" Adolescents and Young Adults"(AYAs). Compared to the general population...
7.
Driessen E, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al.
Leukemia
. 2015 Sep;
30(5):1184-7.
PMID: 26369984
No abstract available.
8.
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grumayer R, Peters C, et al.
Leukemia
. 2015 Mar;
29(8):1648-55.
PMID: 25748682
The prognosis for children with high-risk relapsed acute lymphoblastic leukemia (ALL) is poor. Here, we assessed the prognostic importance of response during induction and consolidation treatment prior to hematopoietic stem...
9.
Lobel U, Trah J, Escherich G
Pediatr Blood Cancer
. 2014 Nov;
62(3):539-41.
PMID: 25360802
Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in characteristics, intensity and time of onset, and depend on the...
10.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Hanenberg H, Janka G, et al.
Klin Padiatr
. 2014 Jul;
226(6-7):332-7.
PMID: 25062112
Background: TEL-AML the most common genetic alteration in childhood precursor B acute lymphoblastic leukemia (BCP-ALL) is associated with a favorable prognosis. Patients And Method: We studied the expression of nerve...